NPCE
NeuroPace, Inc. [NPCE] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
NPCE Stock Summary
In the News
NPCE Financial details
Company Rating
-
Market Cap
382.65M
Income
-36.98M
Revenue
65.42M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
171
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-7.93
Forward P/E
-
PEG
2.36
P/S
5.75
P/B
20.94
P/C
-
P/FCF
-14.16
Quick Ratio
5.67
Current Ratio
6.55
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.44
EPS next Y
-
EPS next Q
-
EPS this Y
-41.47%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-5.78%
Revenue last 5Y
12.09%
Revenue Q/Q
9.65%
EPS Q/Q
-17.86%
-
-
-
-
SMA20
-
SMA50
-18.18%
SMA100
-18.18%
Inst Own
-
Inst Trans
-
ROA
-44%
ROE
-173%
ROC
-0.37%
Gross Margin
72%
Oper. Margin
-53%
Profit Margin
-72%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.795-18.15
52W High
-45.94%
52W Low
+224.33%
RSI
61
Rel Volume
0.73
Avg Volume
103.92K
Volume
75.49K
Perf Week
9.57%
Perf Month
8.35%
Perf Quarter
-13.43%
Perf Half Y
-18.37%
-
-
-
-
Beta
2.09
-
-
Volatility
0.24%, 0.34%
Prev Close
1.25%
Price
9.73
Change
3.84%
Company Profile
- Volume Average 103.92K
- Market Capitalization 382.65M
- Employee 171
- CEO Mr. Joel D. Becker
- Headquarters Mountain View,CA,US
- IPO Date 2021-04-22
-
Website
https://www.neuropace.com 
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
